Ebastine (BioDeep_00000017985)

human metabolite blood metabolite

代谢物信息卡片

1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone

化学式: C32H39NO2 (469.2980634)
中文名称: 依巴斯汀
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: CC(C)(C)C1=CC=C(C=C1)C(=O)CCCN1CCC(CC1)OC(C1=CC=CC=C1)C1=CC=CC=C1
InChI: InChI=1S/C32H39NO2/c1-32(2,3)28-18-16-25(17-19-28)30(34)15-10-22-33-23-20-29(21-24-33)35-31(26-11-6-4-7-12-26)27-13-8-5-9-14-27/h4-9,11-14,16-19,29,31H,10,15,20-24H2,1-3H3

描述信息

Ebastine (trade names Evastin, Kestine, Ebastel, Aleva) is a non-sedating H1 antihistamine. It does not penetrate the blood–brain barrier and thus allows an effective block of the H1 receptor in peripheral tissue without a central side effect, i. e not causing sedation or drowsiness. The basic patent for ebastine in Europe is EP-B-134124. It is often provided in micronised form, due to poor water solubility. (Wikipedia) CYP2J2, an arachidonic acid epoxygenase, is recognized for its role in the first-pass metabolism of astemizole and ebastine. (PMID: 22328583)
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use
D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists
C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
COVID info from COVID-19 Disease Map
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
Ebastine (LAS-W 090) is an orally active, second-generation histamine H1 receptor antagonist. Ebastine can be used for the symptoms of allergic rhinitis and chronic idiopathic urticaria research[1].

同义名列表

20 个代谢物同义名

1-[4-(1,1-Dimethylethyl)phenyl]-4-[4-(diphenylmethoxy)-1-piperidinyl]-1-butanone; 1-(4-tert-butylphenyl)-4-[4-(diphenylmethoxy)piperidin-1-yl]butan-1-one; 4-Diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine; LAS-W 090; LAS W-090; RP 64305; ebastine; Busidril; Evastin; Kestine; Evastel; Ebatrol; Ebastin; Ebastel; Erostin; Bastel; Bactil; Kestin; Aleva; RP64305

数据库引用编号

10 个数据库交叉引用编号

ChEBI: CHEBI:31528
KEGG: C77079
PubChem: 3191
HMDB: HMDB0060159
DrugBank: DB11742
ChEMBL: CHEMBL305660
Wikipedia: Ebastine
CAS: 90729-43-4
PMhub: MS000001540
medchemexpress: HY-B0674

分类词条

Diphenylmethanes

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

9606 - Homo sapiens: -

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

文献列表

Cristina Muntean, Eva Blondeel, Laure Harinck, Kunal Pednekar, Jai Prakash, Olivier De Wever, Jeanne Leblond Chain, Stefaan C De Smedt, Katrien Remaut, Koen Raemdonck. Repositioning the antihistamine ebastine as an intracellular siRNA delivery enhancer. International journal of pharmaceutics. 2023 Sep; 644(?):123348. doi: 10.1016/j.ijpharm.2023.123348. [PMID: 37633539]
Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
Margaret Phiri, Duo Li, Tengfei Li, Shunli Ji, Tang Ling, Xianjing Li, Huaye Gao, Li Ding, Chang Shu. Method development and validation for simultaneous determination of ebastine and its active metabolite carebastine in human plasma by liquid chromatography-tandem mass spectrometry and its application to a clinical pharmacokinetic study in healthy Chinese volunteers. Biomedical chromatography : BMC. 2020 Oct; 34(10):e4904. doi: 10.1002/bmc.4904. [PMID: 32449558]
J Saito, N Yakuwa, N Sandaiji, S Yagishita, H Kawasaki, T Suzuki, K Ozawa, S Kamura, A Yamatani, S Wada, H Sago, A Murashima. Ebastine during pregnancy and lactation in a patient with chronic urticaria: ebastine and carebastine levels in maternal serum, cord blood, breast milk and the infant's serum. Journal of the European Academy of Dermatology and Venereology : JEADV. 2020 Sep; 34(9):e496-e497. doi: 10.1111/jdv.16415. [PMID: 32249465]
Giuseppe Palma, Teresa Pasqua, Giovannino Silvestri, Carmine Rocca, Paola Gualtieri, Antonio Barbieri, Anna De Bartolo, Antonino De Lorenzo, Tommaso Angelone, Ennio Avolio, Gerardo Botti. PI3Kδ Inhibition as a Potential Therapeutic Target in COVID-19. Frontiers in immunology. 2020; 11(?):2094. doi: 10.3389/fimmu.2020.02094. [PMID: 32973818]
Tobie D Lee, Olivia W Lee, Kyle R Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, Bethilehem G Tebase, Carleen Klumpp-Thomas, Robert W Robey, Suresh V Ambudkar, Min Shen, Michael M Gottesman, Matthew D Hall. A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Molecular pharmacology. 2019 11; 96(5):629-640. doi: 10.1124/mol.119.115964. [PMID: 31515284]
Michael Camilleri, Guy Boeckxstaens. Dietary and pharmacological treatment of abdominal pain in IBS. Gut. 2017 05; 66(5):966-974. doi: 10.1136/gutjnl-2016-313425. [PMID: 28232472]
Mira M Wouters, Dafne Balemans, Sander Van Wanrooy, James Dooley, Vincent Cibert-Goton, Yeranddy A Alpizar, Eduardo E Valdez-Morales, Yasmin Nasser, Paul P Van Veldhoven, Winde Vanbrabant, Schalk Van der Merwe, Raf Mols, Bart Ghesquière, Carla Cirillo, Inge Kortekaas, Peter Carmeliet, Willy E Peetermans, Séverine Vermeire, Paul Rutgeerts, Patrick Augustijns, Peter W Hellings, Ann Belmans, Stephen Vanner, David C Bulmer, Karel Talavera, Pieter Vanden Berghe, Adrian Liston, Guy E Boeckxstaens. Histamine Receptor H1-Mediated Sensitization of TRPV1 Mediates Visceral Hypersensitivity and Symptoms in Patients With Irritable Bowel Syndrome. Gastroenterology. 2016 Apr; 150(4):875-87.e9. doi: 10.1053/j.gastro.2015.12.034. [PMID: 26752109]
Daniel R McDougle, Amrita Palaria, Eric Magnetta, Daryl D Meling, Aditi Das. Functional studies of N-terminally modified CYP2J2 epoxygenase in model lipid bilayers. Protein science : a publication of the Protein Society. 2013 Jul; 22(7):964-79. doi: 10.1002/pro.2280. [PMID: 23661295]
W Kang, S Elitzer, K Noh, T Bednarek, M Weiss. Myocardial pharmacokinetics of ebastine, a substrate for cytochrome P450 2J, in rat isolated heart. British journal of pharmacology. 2011 Aug; 163(8):1733-9. doi: 10.1111/j.1476-5381.2011.01338.x. [PMID: 21410688]
Myung-Jae Lee, Heon-Woo Lee, Jong-Min Kang, Ji-Hyung Seo, Seong-Kun Tak, Wangseob Shim, Sung-Vin Yim, Seung Jae Hong, Kyung-Tae Lee. Application of a rapid and selective method for the simultaneous determination of carebastine and pseudoephedrine in human plasma by liquid chromatography-electrospray mass spectrometry for bioequivalence study in Korean subjects. Biomedical chromatography : BMC. 2010 Oct; 24(10):1031-7. doi: 10.1002/bmc.1392. [PMID: 20099369]
Ji-Hong Shon, Chang-Woo Yeo, Kwang-Hyeon Liu, Sang-Seop Lee, In-Jun Cha, Jae-Gook Shin. Itraconazole and rifampin alter significantly the disposition and antihistamine effect of ebastine and its metabolites in healthy participants. Journal of clinical pharmacology. 2010 Feb; 50(2):195-204. doi: 10.1177/0091270009348974. [PMID: 19841159]
Sayaka Kato, Yukio Kato, Tadakatsu Nakamura, Tomoko Sugiura, Yoshiyuki Kubo, Yoshiharu Deguchi, Akira Tsuji. Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Biopharmaceutics & drug disposition. 2009 Dec; 30(9):495-507. doi: 10.1002/bdd.681. [PMID: 19821448]
Jussi Kosonen, Leif Kronberg. The occurrence of antihistamines in sewage waters and in recipient rivers. Environmental science and pollution research international. 2009 Jul; 16(5):555-64. doi: 10.1007/s11356-009-0144-2. [PMID: 19337767]
Naoko Inomata, Satoko Tatewaki, Zenro Ikezawa. Multiple H1-antihistamine-induced urticaria. The Journal of dermatology. 2009 Apr; 36(4):224-7. doi: 10.1111/j.1346-8138.2009.00627.x. [PMID: 19348661]
Dao-rong Xing, Ting-huan Wen, Yang-lin Yu, Zhi-ping Wei, Yi-ming Li, Tian Han. [Urticaria in relation to mite sensitivity and immunotherapy with Injection dermatophagoidei farinae]. Zhongguo ji sheng chong xue yu ji sheng chong bing za zhi = Chinese journal of parasitology & parasitic diseases. 2008 Dec; 26(6):422-7. doi: NULL. [PMID: 19288915]
Robert J Noveck, Richard A Preston, Suzanne K Swan. Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment. Clinical pharmacokinetics. 2007; 46(6):525-34. doi: 10.2165/00003088-200746060-00006. [PMID: 17518511]
Guillermo Gervasini, Sonia Vizcaino, Juan Antonio Carrillo, Maria Jesus Caballero, Julio Benitez. The effect of CYP2J2, CYP3A4, CYP3A5 and the MDR1 polymorphisms and gender on the urinary excretion of the metabolites of the H-receptor antihistamine ebastine: a pilot study. British journal of clinical pharmacology. 2006 Aug; 62(2):177-86. doi: 10.1111/j.1365-2125.2006.02578.x. [PMID: 16842392]
P Chaikin, M S Gillen, M Malik, H Pentikis, G R Rhodes, D J Roberts. Co-administration of ketoconazole with H1-antagonists ebastine and loratadine in healthy subjects: pharmacokinetic and pharmacodynamic effects. British journal of clinical pharmacology. 2005 Mar; 59(3):346-54. doi: 10.1111/j.1365-2125.2005.02348.x. [PMID: 15752381]
Wonku Kang, Kwang-Hyeon Liu, Ji-Young Ryu, Jae-Gook Shin. Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2004 Dec; 813(1-2):75-80. doi: 10.1016/j.jchromb.2004.09.017. [PMID: 15556518]
Katarina Stark, Lydia Schauer, Göran E Sahlén, Gunnar Ronquist, Ernst H Oliw. Expression of CYP4F12 in gastrointestinal and urogenital epithelia. Basic & clinical pharmacology & toxicology. 2004 Apr; 94(4):177-83. doi: 10.1111/j.1742-7843.2004.pto940404.x. [PMID: 15078342]
Kenneth C Lasseter, Stacy C Dilzer, Ramon Vargas, Scott Waldman, Robert J Noveck. Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study. Clinical pharmacokinetics. 2004; 43(2):121-9. doi: 10.2165/00003088-200443020-00004. [PMID: 14748620]
Sandra L Pfister, Nancy Spitzbarth, Darryl C Zeldin, Pierre Lafite, Daniel Mansuy, William B Campbell. Rabbit aorta converts 15-HPETE to trihydroxyeicosatrienoic acids: potential role of cytochrome P450. Archives of biochemistry and biophysics. 2003 Dec; 420(1):142-52. doi: 10.1016/j.abb.2003.09.026. [PMID: 14622984]
Alberto Tedeschi, Lorena Airaghi, Maurizio Lorini, Riccardo Asero. Chronic urticaria: a role for newer immunomodulatory drugs?. American journal of clinical dermatology. 2003; 4(5):297-305. doi: 10.2165/00128071-200304050-00001. [PMID: 12688835]
Hampel Frank, Michael Gillen, Shashank S Rohatagi, Janet Lim, George George. A double-blind, placebo-controlled study of the efficacy and safety of ebastine 20 mg once daily given with and without food in the treatment of seasonal allergic rhinitis. Journal of clinical pharmacology. 2002 Oct; 42(10):1097-104. doi: 10.1177/009127002401382696. [PMID: 12362923]
Masaaki Tagawa, Michiko Kano, Nobuyuki Okamura, Makoto Higuchi, Michiaki Matsuda, Yasuyuki Mizuki, Hiroyuki Arai, Toshihiko Fujii, Sadao Komemushi, Masatoshi Itoh, Hidetada Sasaki, Takehiko Watanabe, Kazuhiko Yanai. Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration. British journal of clinical pharmacology. 2002 Mar; 53(3):296-304. doi: 10.1046/j.0306-5251.2001.01183.x. [PMID: 11874393]
M Tagawa, M Kano, N Okamura, M Higuchi, M Matsuda, Y Mizuki, H Arai, R Iwata, T Fujii, S Komemushi, T Ido, M Itoh, H Sasaki, T Watanabe, K Yanai. Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. British journal of clinical pharmacology. 2001 Nov; 52(5):501-9. doi: 10.1046/j.1365-2125.2001.01471.x. [PMID: 11736858]
M Matsuda, Y Mizuki, Y Terauchi. Simultaneous determination of the histamine H1-receptor antagonist ebastine and its two metabolites, carebastine and hydroxyebastine, in human plasma using high-performance liquid chromatography. Journal of chromatography. B, Biomedical sciences and applications. 2001 Jun; 757(1):173-9. doi: 10.1016/s0378-4347(00)00494-1. [PMID: 11419742]
S Rohatagi, M Gillen, M Aubeneau, C Jan, B Pandit, B K Jensen, G Rhodes. Effect of age and gender on the pharmacokinetics of ebastine after single and repeated dosing in healthy subjects. International journal of clinical pharmacology and therapeutics. 2001 Mar; 39(3):126-34. doi: 10.5414/cpp39126. [PMID: 11396753]
I Tamai, Y Kido, J Yamashita, Y Sai, A Tsuji. Blood-brain barrier transport of H1-antagonist ebastine and its metabolite carebastine. Journal of drug targeting. 2000; 8(6):383-93. doi: 10.3109/10611860008997914. [PMID: 11328664]
H Ohtani, H Sato, T Iga, H Kotaki, Y Sawada. Pharmacokinetic-pharmacodynamic analysis of the arrhythmogenic potency of a novel antiallergic agent, ebastine, in rats. Biopharmaceutics & drug disposition. 1999 Mar; 20(2):101-6. doi: 10.1002/(sici)1099-081x(199903)20:2<101::aid-bdd160>3.0.co;2-l. [PMID: 10206325]
A J Moss, J Morganroth. Cardiac effects of ebastine and other antihistamines in humans. Drug safety. 1999; 21 Suppl 1(?):69-80; discussion 81. doi: 10.2165/00002018-199921001-00009. [PMID: 10597870]
H Fischer, R Gottschlich, A Seelig. Blood-brain barrier permeation: molecular parameters governing passive diffusion. The Journal of membrane biology. 1998 Oct; 165(3):201-11. doi: 10.1007/s002329900434. [PMID: 9767674]
M Y Huang, D Argenti, J Wilson, J Garcia, D Heald. Pharmacokinetics and electrocardiographic effect of ebastine in young versus elderly healthy subjects. American journal of therapeutics. 1998 May; 5(3):153-8. doi: 10.1097/00045391-199805000-00005. [PMID: 10099053]
T Fujii, S Matsumoto, T Hatoyama, H Miyazaki. Studies on the first-pass metabolism of ebastine in rats. Arzneimittel-Forschung. 1997 Aug; 47(8):949-53. doi: NULL. [PMID: 9296281]
C M Ko, I Ducic, J Fan, Y M Shuba, M Morad. Suppression of mammalian K+ channel family by ebastine. The Journal of pharmacology and experimental therapeutics. 1997 Apr; 281(1):233-44. doi: NULL. [PMID: 9103502]
H S Pentikis, M Y Huang, M B Dorr, D L Heald. The effect of food on the bioavailability of ebastine. American journal of therapeutics. 1997 Feb; 4(2-3):80-4. doi: 10.1097/00045391-199702000-00005. [PMID: 10423596]
E L Mariño, J M Jansat, M A March, C F Lastra. Parametrization by nonlinear regression analysis of the active acid metabolite of ebastine using different weighting methods. International journal of clinical pharmacology and therapeutics. 1996 Dec; 34(12):546-9. doi: NULL. [PMID: 8996850]
A Puigdemont, M Queralt, J M Jansat, A Martinez-Tobed. Pharmacokinetic and pharmacodynamic studies of the histamine H1-receptor antagonist ebastine in dogs. The Journal of pharmacy and pharmacology. 1994 Jul; 46(7):596-9. doi: 10.1111/j.2042-7158.1994.tb03864.x. [PMID: 7996390]
K Yoshida, T Hatoyama, T Fujii, A Kagemoto, H Miyazaki, S Naruto. Identification of rat faecal metabolites of ebastine by B/E linked scanning liquid secondary ion mass spectrometry. Biological mass spectrometry. 1994 Jul; 23(7):385-90. doi: 10.1002/bms.1200230702. [PMID: 7915143]
T Fujii, K Tanaka, S Matsumoto, T Hatoyama, N Nomura, M Tagawa, H Miyazaki. Absorption, distribution, metabolism and excretion of [14C]ebastine after repeated oral administration in rats. Arzneimittel-Forschung. 1994 Apr; 44(4):538-43. doi: NULL. [PMID: 7912072]
T Fujii, S Matsumoto, H Amejima, T Hatoyama, M Nakao, A Kagemoto, K Tanaka, H Miyazaki. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats. Arzneimittel-Forschung. 1994 Apr; 44(4):527-38. doi: NULL. [PMID: 7912071]
T Yamaguchi, T Hashizume, M Matsuda, M Sakashita, T Fujii, Y Sekine, M Nakashima, T Uematsu. Pharmacokinetics of the H1-receptor antagonist ebastine and its active metabolite carebastine in healthy subjects. Arzneimittel-Forschung. 1994 Jan; 44(1):59-64. doi: NULL. [PMID: 7907873]
M Matsuda, M Sakashita, Y Mizuki, T Yamaguchi, T Fujii, Y Sekine. Comparative pharmacokinetics of the histamine H1-receptor antagonist ebastine and its active metabolite carebastine in rats, guinea pigs, dogs and monkeys. Arzneimittel-Forschung. 1994 Jan; 44(1):55-9. doi: NULL. [PMID: 7907872]
J Van Rooij, H C Schoemaker, R Bruno, J F Reinhoudt, D D Breimer, A F Cohen. Cimetidine does not influence the metabolism of the H1-receptor antagonist ebastine to its active metabolite carebastine. British journal of clinical pharmacology. 1993 Jun; 35(6):661-3. doi: 10.1111/j.1365-2125.1993.tb04199.x. [PMID: 8101096]
F E Simons, W T Watson, K J Simons. Pharmacokinetics and pharmacodynamics of ebastine in children. The Journal of pediatrics. 1993 Apr; 122(4):641-6. doi: 10.1016/s0022-3476(05)83555-3. [PMID: 8096545]
M J Mattila, K Aranko, T Kuitunen. Diazepam effects on the performance of healthy subjects are not enhanced by treatment with the antihistamine ebastine. British journal of clinical pharmacology. 1993 Mar; 35(3):272-7. doi: 10.1111/j.1365-2125.1993.tb05694.x. [PMID: 8097102]
M J Mattila, T Kuitunen, Y Plétan. Lack of pharmacodynamic and pharmacokinetic interactions of the antihistamine ebastine with ethanol in healthy subjects. European journal of clinical pharmacology. 1992; 43(2):179-84. doi: 10.1007/bf01740667. [PMID: 1358620]
J Vincent, R Liminana, P A Meredith, J L Reid. The pharmacokinetics, antihistamine and concentration-effect relationship of ebastine in healthy subjects. British journal of clinical pharmacology. 1988 Nov; 26(5):497-502. doi: 10.1111/j.1365-2125.1988.tb05288.x. [PMID: 2905150]